Home › NDC Lookup › RxCUI directory › RxCUI 2105649

Larotrectinib 20 MG/ML Oral Solution — RxCUI 2105649

RxNorm drug concept · Semantic clinical drug
RxCUI 2105649 Semantic clinical drug · SCD ● Current RxNorm concept 7 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2105649
Official nameLarotrectinib 20 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslarotrectinib 20 MG per 1 ML Oral Solution; larotrectinib 20 MG in 1 mL Oral Solution; larotrectinib 20 MG (as 24.6 MG larotrectinib sulfate) per 1 ML Oral Solution
FDA products mapped7
Package NDCs mapped7
Reported Medicaid activity (SDUD)38 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Larotrectinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Vitrakvi isn't tied to one specific cancer type — it targets a specific genetic change called an NTRK gene fusion that can show up in many different solid tumors, in both adults an...
  • What kind of cancer is Vitrakvi actually used for?
  • Good news — you can take Vitrakvi with or without food, whichever is more convenient or comfortable for you. A high-fat meal can slightly change how quickly the drug is absorbed, b...
  • Can I take Vitrakvi with food, or does it have to be on an empty stomach?
📖 Read our full Larotrectinib guide →

🕸️ Concept Web — How Larotrectinib 20 MG/ML Oral Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Larotrectinib 20 MG/ML Oral Solution RxCUI 2105649

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Larotrectinib 2105628
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vitrakvi 2105640
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Larotrectinib Oral Solution 2105648
    • Larotrectinib Oral Liquid Product 2105647
    • Larotrectinib Oral Product 2105630
    • Larotrectinib Oral Solution [Vitrakvi] 2105651
    • Vitrakvi Oral Liquid Product 2105652
    • Vitrakvi Oral Product 2105643
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Larotrectinib 20 MG/ML SCDC · 2105646
  • Larotrectinib Oral Solution SCDF · 2105648
  • Larotrectinib Oral Liquid Product SCDG · 2105647
  • Larotrectinib Oral Product SCDG · 2105630

Brand-Name Concepts

  • Larotrectinib 20 MG/ML Oral Solution [Vitrakvi] SBD · 2105653
  • Larotrectinib 20 MG/ML [Vitrakvi] SBDC · 2105650
  • Larotrectinib Oral Solution [Vitrakvi] SBDF · 2105651
  • Vitrakvi Oral Liquid Product SBDG · 2105652
  • Vitrakvi Oral Product SBDG · 2105643
  • Vitrakvi BN · 2105640

📦 FDA Products & Package NDCs

7 products · 7 package NDCs
7 package NDCs map to RxCUI 2105649 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50419-0390-01 60 CAPSULE in 1 BOTTLE (50419-390-01) VITRAKVI Bayer HealthCare Pharmaceuticals Inc. 2019-07-26
50419-0391-01 60 CAPSULE in 1 BOTTLE (50419-391-01) VITRAKVI Bayer HealthCare Pharmaceuticals Inc. 2019-07-26
50419-0392-01 100 mL in 1 BOTTLE (50419-392-01) VITRAKVI Bayer HealthCare Pharmaceuticals Inc. 2019-07-26
50419-0393-03 2 BOTTLE in 1 CARTON (50419-393-03) / 50 mL in 1 BOTTLE (50... VITRAKVI Bayer HealthCare Pharmaceuticals Inc. 2022-12-06
71777-0390-01 60 CAPSULE in 1 BOTTLE (71777-390-01) VITRAKVI Loxo Oncology, Inc. 2018-11-26
71777-0391-01 60 CAPSULE in 1 BOTTLE (71777-391-01) VITRAKVI Loxo Oncology, Inc. 2018-11-26
71777-0392-01 100 mL in 1 BOTTLE (71777-392-01) VITRAKVI Loxo Oncology, Inc. 2018-11-26
Observed labelers: Bayer HealthCare Pharmaceuticals Inc. (4) · Loxo Oncology, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.